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Abstract
Background: Interleukin-8 (IL-8) is a potent chemo-attractant cytokine responsible for neutrophil infiltration in
lungs with idiopathic pulmonary fibrosis (IPF). The IL-8 protein and mRNA expression are increased in the lung
with IPF. We evaluated the effect of single nucleotide polymorphisms (SNPs) of the IL-8 gene on the risk of IPF.
Methods: One promoter (rs4073T>A) and two intronic SNPs (rs2227307T>G and rs2227306C>T) of the IL-8 genes
were genotyped in 237 subjects with IPF and 456 normal controls. Logistic regression analysis was applied to
evaluate the association of these SNPs with IPF. IL-8 in BAL fluids was measured using a quantitative sandwich
enzyme immunoassay, and promoter activity was assessed using the luciferase reporter assay.
Results: The minor allele frequencies of rs4073T>A and rs2227307T>G were significantly lower in the 162 subjects
with surgical biopsy-proven IPF and 75 subjects with clinical IPF compared with normal controls in the recessive
model (OR = 0.46 and 0.48, p = 0.006 and 0.007, respectively). The IL-8 protein concentration in BAL fluids
significantly increased in 24 subjects with IPF compared with 14 controls (p = 0.009). Nine IPF subjects
homozygous for the rs4073 T>A common allele exhibited higher levels of the IL-8 protein compared with six
subjects homozygous for the minor allele (p = 0.024). The luciferase activity of the rs4073T>A common allele was
significantly higher than that of the rs4073T>A minor allele (p = 0.002).
Conclusion: The common allele of a promoter SNP, rs4073T>A, may increase susceptibility to the development of
IPF via up-regulation of IL-8.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastating dis-
ease of the idiopathic interstitial pneumonia family. It
predominantly affects the lung parenchyma and is char-
acterized by progressive dyspnea and worsening lung
function [1]. Although the pathogenesis of IPF is largely
unknown, a current hypothesis suggests aberrant wound
healing of ongoing alveolar epithelial injury and repair
associated with the formation of patchy fibroblast-myofi-
broblast foci, which evolve to fibrosis [2,3]. The pro-
cesses of inflammation and fibrosis likely involve an
interaction between environmental triggers and genetic
background [2]. Supporting evidence for the genetic
background for pulmonary fibrosis is the familial occur-
rence, as seen in familial IPF [4]. However, the nature of
the genetic basis for sporadic IPF has not been evaluated
due to low disease incidence. Recent reports suggest
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contribute to the development of lung fibrosis [5-7].
Characteristic of IPF is neutrophilia of the bronchoal-
veolar lavage fluid. The recruitment and activation of
neutrophils plays a fundamental role in the development
of lung injury, which precedes aberrant wound repair in
the pathogenesis of IPF[3]. Interleukin-8 (IL-8) acts as a
potent chemoattractant for neutrophils [8]. The IL-8
protein and mRNA expression are increased in the BAL
fluid and the alveolar macrophages of patients with IPF
[9]. An animal study also confirmed the role of IL-8 in
p u l m o n a r yf i b r o s i sb yd e m o n strating that bleomycin-
induced lung fibrosis is attenuated by the neutralization
of IL-8[10]. In addition to promoting inflammation, IL-8
has angiogenic activity[11,12]. Thus, genetic alterations
of IL-8 may be related to the development of IPF.
In humans, the gene encoding IL-8 is located on chro-
mosome 4q12-q21 and consists of four exons and three
introns [13]. Polymorphisms of IL-8 are associated
increased risk of developing various cancers [14]. SNPs
within IL8 have been reported as candidates for cystic
fibrosis lung disease, a neutrophil-dominant inflamma-
tory lung disease like IPF [15]. Although a previous
study reported no association between IPF risk and
these SNPs [16], the study had a small sample size of 71
patients with IPF including 31 surgical biopsy-proven
cases. Thus, a study with a relatively large sample size
was needed to examine the genetic effect of polymorph-
isms of the IL-8 gene on the risk of IPF. We genotyped
and compared the frequencies of three SNPs of the IL-8
genes in 237 subjects with IPF and 456 normal controls
and evaluated their association with the development of
IPF, as well as performed functional validation.
Methods
Study subjects
Subjects with IPF were recruited from the Korean
Cohort of Interstitial Lung Disease. The study popula-
tion comprised 237 patients with IPF recruited from
January 1984 to November 2004 from eight university
hospitals. Normal (control) subjects (n = 456) were the
spouses of the patients or volunteers from the general
population. Control subjects were at least 50 years old,
had no respiratory symptoms, exhibited normal FVC
and FEV1 (>75% of the predicted value), and normal
findings on a simple chest posterior-anterior view x-ray.
The diagnosis of IPF was based on an international con-
sensus statement by ATS/ERS with compatible findings
via surgical lung biopsy (n =1 6 2 )o ru s i n gr a d i o - c l i n i c a l
criteria (n = 75), i.e., the presence of clinical, functional,
and high-resolution computed tomography patterns
strongly consistent with IPF. None of the patients with
IPF had any evidence of the underlying collagen vascular
diseases clinically or by laboratory diagnosis. The
institutional review board by Soonchunhyang University
hospital for human studies approved the protocol, and
informed written consent was obtained from all subjects.
Genotyping with fluorescence polarization detection
To genotype polymorphic sites, primers and probes
were designed for TaqMan
® 17. Primer Express
(Applied Biosystems, Foster, CA, USA) was used to
design both the PCR primers and the MGB TaqMan
probes. One allelic probe was labeled with the FAM dye
and the other was labeled with fluorescent VIC dye. The
PCRs were run on the TaqMan Universal Master mix
without UNG (Applied Biosystems), with a PCR primer
concentration of 900 nM and a TaqMan MGB-probe
concentration of 200 nM. The reactions were carried
out in a 384-well format in a total reaction volume of
50 ul using 20 ng of the genomic DNA. The plates then
were placed in a thermal cycler (PE 9700, Applied Bio-
systems) and heated to 50°C for 2 min and 95°C for 10
min followed by 40 cycles of 95°C for 15 sec and 60°C
for 1 min. The TaqMan assay plates were then trans-
ferred to a Prism 7900HT instrument (Applied Biosys-
tems), which measured the fluorescence intensity in
each well of the plate. The fluorescence data files from
each plate were analyzed using automated software
(SDS 2.1). Detailed information concerning the primers
is presented in additional file 1, table S1.
Bronchoalveolar lavage and enzyme immunoassay of IL-8
BAL had been performed in the most affected lobe by
computed tomography in the 24 subjects without any
immunosuppressive therapy and in the right middle
lobe of 14 normal controls, as described previously[17].
The supernatant was separated from cell pellets by cen-
trifugation at 500 × g for 5 minutes. IL-8 in BAL fluids
was measured using a quantitative sandwich enzyme
immunoassay kit (BD Pharmingen, San Diego, CA,
USA). The lower limit of detection for IL-8 was 15.6
pg/mL. Values below this limit were assumed to be 0
pg/mL for the statistical analysis. The inter- and intra-
assay coefficients of variance were below 10%. Protein
concentration of BAL samples was measured for stan-
dardization using a micro BCA protein assay kit (Pierce,
Rockford, IL, USA).
Assessing promoter activity using the luciferase reporter
assay
The promoter region of IL-8 was amplified using PCR.
The genomic DNA fragment was isolated from B cell
lines of the IPF subjects using a genomic DNA prepara-
tion kit (Gentra, Ipswich, MA, USA). The first PCR pro-
duct was amplified using the following primers: forward;
5’-TGCCTTTGGAAGATTCTGCT-3’, reverse; 5’-
GCCAGCTTGGAAGTCATGTT-3’.T h ep r i m a r yP C R
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a nested PCR reaction using the nested primers contain-
ing restriction enzyme sequences (forward; 5’-ACTGG-
TACC(KpnI)ACATTACTCAGAAA-3’,r e v e r s e ;5 ’-
CCTACGCGT(MluI)GTCTCTGAAAGTTTG-3’)f o r
construction of the IL8 reporter plasmid. The amplified
fragment of the promoter region of the IL8 gene (-79 to
-743 bp from the transcription start site) was cloned
using the pGEM-T easy vector system (Promega Co.
Madison, WI, USA), was ligated with pGL-3 basic Luc+
reporter vector (Promega). Cloned DNA sequences were
determined by a DNA direct-sequencing service (Geno-
tech, Daejeon, Korea). One day before transfection, 293
T cells were seeded at 5 × 10
5 cells per well (6-well
plate) in 2 ml with 10% FBS. A 2-μg aliquot of the IL8-
pGL3 basic constructor plasmid and 50 ng of PSV-
galactosidase reporter vector (Promega, transfection
parameter) were diluted in 250 μlO p t M E M( G I B C O
BRL, Burlington, MD, USA) without serum. The 4 μlo f
lipofectamine 2000 (recommended DNA ug: lipofecta-
mine ul = 1:2, Invitrogen, Carlsbad, CA) was diluted in
250 ul OptMEM (GIBCO BRL) per well. The diluted
DNA was combined with the diluted lipid (total volume
500 μl per well). Then, 500 μl of transfection complex
was added, and the cells were incubated at 37°C with
5% CO2 in humidified air for 48 h. b-galactosidase
activity was measured by ortho-nitrophenyl-D-galacto-
pyranoside (ONPG) hydrolysis using b-Gal Assay kit
(Promega). The cells were solubilized by scraping with
400 μl of cell lysis buffer of Luciferase Assay System kit
(Promega). Luciferase activity was measured using the
Luciferase Assay System and luminometer (VICTOR3,
Perkinelmer, Waltham, MA, USA). And the relative
luciferase activity was normalized to the protein concen-
tration and b-galactosidase activity.
Statistics
We applied widely used measures of linkage disequili-
brium to all pairs of biallelic loci: Lewontin’sD ’ (|D’|)
[18] and r
2. Haplotypes of each individual were inferred
using the PHASE algorithm (ver. 2.0) developed by Ste-
phens et al. [19]. The genotype and haplotype distribu-
tions were analyzed using logistic regression models
with age (continuous value), gender (male = 0, female =
1), smoking status (non-smoker = 0, ex-smoker = 1,
smoker = 2), atopy (absence = 0, presence = 1), and
BMI as covariates. Cox models were used for calculating
relative hazards and P-values controlling age, sex and
smoking status[20]. Mantel-Haenszel chi-square (MHC)
tests were used to test for trend in the categorical analy-
sis. The data were managed and analyzed using SAS
version 9.1 (SAS Inc., Cary, NC, USA). Statistical power
of single associations was calculated with false-positive
rate of 5% and four given MAFs and sample sizes and
assuming a relative risk of 1.5, using PGA (Power for
Genetic Association Analyses) software [21].
Results
Clinical profiles of study subjects
Clinical profiles of the study subjects are summarized in
Table 1. In total, 237 subjects with IPF and 456 normal
controls were recruited. Age and sex ratios of normal con-
trols were similar to those of the subjects with IPF. The
162 subjects with biopsy-proven IPF and the 75 subjects
with clinical IPF had similar age and sex ratios. The fre-
quency of current smokers and ex-smokers were higher in
the subjects with both biopsy-proven IPF and clinical IPF
compared with that in normal controls. The patients with
IPF had a significant reduction in FVC when compared
with normal control subjects (p < 0.01). The subjects with
biopsy-proven IPF and those with clinical IPF had the
comparable impairment of FVC and DLCO.
Association of SNPs within the IL8 gene with
development of IPF
One promoter SNP (rs4073T>A) and two intronic SNPs
(rs2227307T>G and rs2227306C>T) within the IL8 gene
were genotyped in IPF patients and normal subjects (see
Additional file 2, figure S1). Frequencies and heterozyg-
osities of the SNPs are presented in additional file 3,
table S2. Genotype distributions of the SNPs were in
Hardy-Weinberg equilibrium (p < 0.05). The LDs were
calculated, and haplotypes of IL8 polymorphisms were
constructed (see Additional file 2, figure S1 B and C).
Three major haplotypes with over 5% of MAF were
detected. However, IL8-ht1 and IL8-ht2 were not ana-
lyzed due to their equivalency with IL8 rs4073 and L8
rs2227306, respectively. IL8 rs4073 and rs2227307 were
significantly associated with a decreased risk of develop-
ing IPF and clinical IPF in the recessive model (OR =
0.46 and OR = 0.48, p = 0.006 and p = 0.007, respec-
tively; Table 2). The minor allele frequencies of
Table 1 Clinical profiles of study subjects
Description Normal
controls
IPF Clinical-IPF
N 456 162 75
Age, yr (range) 62 (50-87) 58 (41-83) 66 (47-83)
Sex (male/female) 278/178 112/50 51/24
Current Smoker (%)/Ex-
smoker (%)
13.8/14.4 28.4/30.2 24.0/28.0
FVC % pred. 98.70 ± 16.73 72.56 ± 17.37 70.94 ± 17.28
DLCO % pred. ND 66.60 ± 19.51 60.71 ± 22.05
IPF: Idiopathic pulmonary fibrosis
FVC: forced expiratory vital capacity
DLCO: Carbon Monoxide Diffusing Capacity
pred.: prediction
ND: not determined
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in the subjects with IPF compared with that in normal
controls (33.7% vs. 36.8% and 33.6% and 36.7%, respec-
tively). When the study subjects were stratified by gen-
der, the association of the two SNPs was restricted to
male gender (Table 3).
Association of rs4073T>A within the IL-8 gene with IL-8
protein levels in BAL fluids
The amount of IL-8 protein was measured in BAL
fluids from 24 subjects with IPF and 14 NC. IL-8
concentrations were significantly increased in IPF
patients compared with NC (9.24 ± 1.11 pg/mg of pro-
tein vs. 1.71 ± 0.27 pg/mg of protein, p = 0.009, Figure
1). A total of 15 subjects with IPF were genotyped, and
the subjects with IPF exhibiting rs4073T>A, a common
allele homozygote, had a higher level of IL-8 protein
(27.01 ± 3.45 pg/mg of protein) than of minor allele
homozygotes (2.35 ± 0.46 pg/mg of protein, p = 0.024).
The IL-8 concentration in BAL fluids did not differ
among individuals with the rs2227307T>G genotype
(data, not shown).
Table 2 The association of IL8 SNPs with the risk of idiopathic pulmonary fibrosis (IPF)
rs s Distribution Codominant Dominant Recessive MAF Statistical
power
Case NC OR(95%CI) P Pcorr OR(95%
CI)
P Pcorr OR(95%
CI)
P Pcorr Case NC
rs4073 T 87
(41.63%)
191
(42.16%)
AT 103
(49.28%)
191
(42.16%)
0.84(0.65-
1.08)
0.17 0.22 1.00(0.71
-1.42)
0.99 1 0.46
(0.26-
0.80)
0.006 0.008 0.337 0.368 82.2%
A 19(9.09%) 71
(15.67%)
rs2227307 T 94
(42.34%)
191
(42.35%)
GT 107
(48.20%)
189
(41.91%)
0.83(0.65-
1.06)
0.14 0.19 0.97(0.69
-1.37)
0.87 1 0.48
(0.28-
0.82)
0.007 0.009 0.336 0.367 93.5%
G 21(9.46%) 71
(15.74%)
rs2227306 C 103
(48.13%)
216
(47.58%)
CT 95
(44.39%)
196
(43.17%)
0.92(0.70-
1.19)
0.51 0.67 0.97(0.69
-1.36)
0.84 1 0.70(0.37-
1.30)
0.26 0.34 0.297 0.308 79.9%
T 16(7.48%) 42(9.25%)
IL8_ht3 -/- 175
(91.15%)
398
(87.86%)
ht3/- 16(8.33%) 55
(12.14%)
0.65(0.37-
1.16)
0.15 0.19 0.61(0.34
-1.10)
0.10 0.13 . . . 0.047 0.061 35.6%
ht3/
ht3
1(0.52%) 0(0.00%)
* Logistic models were used for calculating odd ration and p-values in recessive model controlling for age, sex, and smoking status as covariates.
NC: normal controls
MAF: Minor allele frequency
Table 3 The association of IL8 SNPs with the risk of idiopathic pulmonary fibrosis (IPF) by gender
Male Female
MAF OR(95%CI)* P* MAF OR(95%CI)* P*
IPF and Clinical IPF (n = 152) NC (n = 178) IPF and Clinical IPF (n = 70) NC (n = 276)
0.340 0.394 0.51 (0.26-0.97) 0.04 0.331 0.351 0.53 (0.18-1.57) 0.25
0.336 0.394 0.49 (0.26-0.93) 0.03 0.336 0.350 0.57 (0.20-1.64) 0.30
0.288 0.326 0.83 (0.39-1.75) 0.62 0.316 0.297 0.64 (0.19-2.24) 0.49
0.064 0.071 . . 0.008 0.054 . .
* Logistic models were used for calculating odd ration and p-values in recessive model controlling for age, sex, and smoking status as covariates.
NC: normal controls
MAF: Minor allele frequency
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alleles of the IL8 promoter rs4073T>A
Given that the rs4073T>A is located in the promoter
region, we investigated the promoter activity of
rs4073T>A using luciferase reporter assay. The lucifer-
ase activity was adjusted by pGL3 basic vector, and the
yield of DNA transfection adjusted using pSV-b-galacto-
sidase (+) vector and ONPG activity. The luciferase
activity of the rs4073T>A TT allele was significantly
higher than that of the rs4073T>A AA allele (25.2 ± 2.8
vs. 6.8 ± 0.7, p = 0.002, Figure 2).
Discussion
Our logistic regression analysis of a case-control study
determined that the IL8 rs4073T>A and rs2227307T>G
SNPs from the promoter region are associated with
development of IPF. The frequencies of the minor allele
of the two SNPs were significantly decreased in IPF sub-
jects compared with normal controls. These are the first
data to indicate that the common alleles may increase
susceptibility to development of IPF. Several reports
have shown a relationship between IL8 gene polymorph-
isms and human lung diseases [22-26]. Two SNPs in the
IL8 genes (rs4073 and rs2227307) were evaluated in
patients with systemic sclerosis with (n = 78) or without
fibrosing alveolitis (n = 50), those with cryptogenic
fibrosing alveolitis (n = 71), and normal healthy subjects
in the UK [16]. These study reported no association of
the SNPs of IL8 with the risk of pulmonary fibrosis. The
discrepancy between ours and the previously reported
results may be due to the small study population in the
previous study[16] or to ethnicity differences between
study cohorts, as the minor allele frequency of
rs4073T>A was 33.7% in our study subjects with IPF,
whereas it was 56% in the UK study. Interestingly, the
rs4073T>A polymorphism has recently been reported to
b ear i s kf a c t o ro fo t h e rl u n gdiseases, including bron-
chial asthma [23] and bronchiolitis, caused by respira-
tory syncytial virus [22,24]. In addition, Hillian AD and
coworkers reported an association of the rs 4073 T>A
and cystic fibrosis when the analysis was restricted to
male subjects. In the present study, the SNP was also
significantly associated with IPF restricted to male gen-
der[15]. This data suggest that the SNP may have a
genetics effect on IL-8 gene expression in male gender,
but not in female gender. We could not explain the
restriction of the SNP to male gender. The location of
IL-8 is in chromosome 4q13-q21, and the transcription
factor supposed to bind to the SNP: eEF1A1 is in chro-
mosome 6q14.1. Plasma IL-8 levels were reported to be
similar in the subjects with male or female gender fol-
lowing sever trauma [15]. Further study on the associa-
tion restricted to male would be performed.
We did not validate the association between the SNPs of
the IL-8 gene in an independent replication population.
We evaluate the effect of the SNP on IL-8 gene or protein
expression instead. We measured IL-8 protein concentra-
tions in the lung. IL-8 protein was increased in the BAL
Figure 1 Levels of IL-8 protein of in BAL fluid collected from
normal controls and subjects with IPF. NC: normal controls, IPF:
Surgical IPF, A: IPF subjects having rs4073 TT alleles, T: IPF subjects
having rs4073 AA alleles. Levels of IL-8 protein were normalized with
BAL protein concentration.
Figure 2 Comparison of luciferase activity between rs40730TT
and rs40703AA alleles. The luciferase activity adjusted by pGL3
basic vector and the yield of DNA transfection adjusted using pSV-
b-galactosidase (+) vector and ONPG activity.
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The IL-8 protein level in BAL fluid was significantly
increased in the subjects with IPF having the common
allele of rs4073T>A compared to those with the minor
allele. This result indicates that the rs4073T>A allele
within the promoter may result in increased IL-8 produc-
tion when compared with the minor allele.
The promoter activity was examined using a luciferase
reporter vector, and the promoter activity of the
rs4073T>A TT allele was significantly stronger than that
of the rs4073T>A AA allele. This is in accordance with a
previous study, which reported that the rs4073T>A TT
allele exhibited 2- to 5-fold stronger transcriptional activ-
ity than did the rs4073T>A AA counterpart [27]. Given
that high IL-8 concentrations in BAL fluid were asso-
ciated with the common allele of rs4073 T>A in the pre-
sent study, our luciferase data confirm that the rs4073 T
allele on the promoter may enhance the IL-8 transcrip-
tion compared with the rs4073 A allele. Putative tran-
scription factor binding sites in the promoter of the IL8
gene were searched using the TFSEARCH and TESS
websites. The candidate binding protein for the transcrip-
tion of IL8 at rs4073 was eEF1A1 (see Additional file 4,
figure S2). The eEF1A family consists of two members,
eEF1A1 and eEF1A2 [28]. Thus, eEF1A1 may regulate
the activation and production of IL-8 as a transcription
enhancer or inducer; this is a topic for future research.
In summary, we evaluated the genetic effect of IL-8
gene polymorphisms on the risk of IPF using a relatively
large size population of subjects with IPF and normal
controls. Logistic regression analysis demonstrated that
the minor allele frequencies of rs4073T>A was signifi-
cantly lower in the subjects with IPF compared with
that in normal controls. The subjects with IPF homozy-
gous for the rs4073T>A common allele exhibited signifi-
cantly higher IL-8 protein concentrations in BAL fluids
and enhanced luciferase activities compared with those
homozygous for the rare allele. This study shows that
the IL8 rs4073 T allele is significantly associated with an
increased risk of IPF in the Korean population and this
effect may result from the up-regulation of IL-8 protein
synthesis in the lung. Our results may provide the clue
of the genetic contribution to the pathogenesis of IPF.
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Additional file 1: The fluorescence labeled allelic probe for
amplification of IL8, IL8RA and IL8RB genes. The data provided
represent the probe for amplification of IL8, IL8RA and IL8RB genes.
Additional file 2: SNPs on the map of the IL8 gene, linkage
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Hardy-Weinberg equilibrium (HWE) of IL8 gene polymorphisms. The
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Additional file 4: The candidate binding protein for the
transcription of IL8 at rs4073. The figure provided represent the
putative transcription factor binding sites in the promoter of the IL8
gene.
Abbreviations list
(IPF): Idiopathic pulmonary fibrosis; (IL-8): Interleukin-8; (ONPG): ortho-
nitrophenyl-D-galactopyranoside; (|D’|): Lewontin’sD ’; (MHC): Mantel-
Haenszel chi-square;
Acknowledgements
Declaration of all sources of funding: This study was supported by a grant
from the Korea Healthcare Technology R&D Project, Ministry for Health,
Welfare, and Family Affairs, Republic of Korea (A090548). BAL samples were
generously provided by a Collaborative Biobank of Korea in Soonchunhyang
University Bucheon Hospital.
Korea Genetic Study Group for Interstitial Lung Diseases;
Soonchunhyang Univ. Hosp.; Seoul National Univ. Hosp.; Hallym Univ. Hosp.;
Dankook Univ. Hosp.; Kachun Univ.
Gil Hosp.; Chung-Ang Univ. Hosp.; Sungkyunkwan Univ.; Asan Medical
Center-Ulsan Univ.; SNP Genetics, Inc.
Author details
1Div. of Allergy and Respiratory Medicine, Dept. of Internal Medicine,
Soonchunhyang Univ. Bucheon Hospital, 1174, Jung-dong, Wonmi-gu,
Bucheon, 420-020, Korea.
2Dept. of Genetic Epidemiology, SNP-Genetics Inc.,
B-1407, WooLim Lion’s Valley, 371-28 Gasan-Dong, Geumcheon-Ku, Seoul,
153-803, Korea.
3Div. of Radiology, Soonchunhyang Univ. Bucheon Hosp.,
1174, Jung-Dong, Wonmi-Gu, Bucheon, Gyeonggi-Do, 420-020, Korea.
4Div.
of Thoracic and Cardiovascular Surgery, Soonchunhyang Univ. Bucheon
Hosp., 1174, Jung-Dong, Wonmi-Gu, Bucheon, Gyeonggi-Do, 420-020, Korea.
5Div. of Allergy and Respiratory Medicine, Soonchunhyang Univ. Seoul Hosp.,
657-58, Hannam-dong, Yongsan-gu, Seoul, 140-743, Korea.
6Dept. of Internal
Medicine, Seoul National Univ. Hosp., 28 Yongon-dong, Seoul, Korea.
7Dept.
of Respiratory and Critical Care Medicine, Hallym Univ., Korea.
8Dept. of
Internal Medicine, College of Medicine, Dankook Univ., Cheonan, Korea.
9Div.
of Pulmonary Medicine, Dept. of Internal Medicine, Gachon Medical School
Gil Medical Center, Korea.
10Department of Internal Medicine, Chung Ang
University College of Medicine, Seoul, Korea.
11Div. of Pulmonary and Critical
Care Medicine, Samsung Medical Center, Sungkyunkwan Univ. School of
Medicine, Seoul, Korea.
12Dept. of Life Science, Sogang Univ., Sinsu-dong,
Mapo-gu, Seoul, 121-742, Korea.
13Div. of Pulmonary and Critical Care
Medicine, Asan Medical Center, Univ. of Ulsan, Asanbyungwon-gil, Songpa-
gu, Seoul, 138-736, Korea.
14Dept. of Medicine, Armed Force Capital Hospital,
Bundang-gu, Seongnam-si, Kyonggi-do, Korea.
Authors’ contributions
MHA performed all experimental steps; BLP, SHL, and HDS analyzed statistics
and wrote the manuscript; SWP, JSP, DJK and ASJ provided experimental
assistance; JSP, HKS, SU, YK, YWK, SKH, KSJ, KYL, SHJ, JWP, BWC, IWP, MPC,
JWS, DSK and YSS supervised this project; CSP conceptualized of the study
and wrote the first draft of the manuscript. All authors read and approved
the final manuscript.
The authors thank the editors from textcheck.com, both native speakers of
English, for their proofreading for grammar and typographic errors. For a
certificate, see http://www.textcheck.com/certificate/ox3Vhg.
Competing interests
The authors declare that they have no competing interests.
Received: 13 January 2011 Accepted: 8 June 2011
Published: 8 June 2011
Ahn et al. Respiratory Research 2011, 12:73
http://respiratory-research.com/content/12/1/73
Page 6 of 7References
1. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and
treatment. International consensus statement. American Thoracic Society
(ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care
Med 2000, 161(2 Pt 1):646-664.
2. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med
2001, 345(7):517-525.
3. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and
evolving hypotheses about its pathogenesis and implications for
therapy. Ann Intern Med 2001, 134(2):136-151.
4. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ: Adult familial
cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000,
55(2):143-146.
5. Bremer LA, Blackman SM, Vanscoy LL, McDougal KE, Bowers A,
Naughton KM, Cutler DJ, Cutting GR: Interaction between a novel TGFB1
haplotype and CFTR genotype is associated with improved lung
function in cystic fibrosis. Hum Mol Genet 2008, 17(14):2228-2237.
6. Grutters JC, du Bois RM: Genetics of fibrosing lung diseases. Eur Respir J
2005, 25(5):915-927.
7. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J: Th1/Th2
cytokine gene polymorphisms in patients with idiopathic pulmonary
fibrosis. Tissue Antigens 2006, 67(3):229-232.
8. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K: Properties of the
novel proinflammatory supergene “intercrine” cytokine family. Annu Rev
Immunol 1991, 9:617-648.
9. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P,
Black CM, Laurent GJ, Davies BH, Jeffery PK: Interleukin-8. Differential
expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir
Crit Care Med 1995, 151(5):1604-1612.
10. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE,
Burdick MD, Kunkel SL, Strieter RM: Neutralization of the CXC chemokine,
macrophage inflammatory protein-2, attenuates bleomycin-induced
pulmonary fibrosis. J Immunol 1999, 162(9):5511-5518.
11. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H,
Kondo T, Nukiwa T: Heterogeneous increase in CD34-positive alveolar
capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2004, 169(11):1203-1208.
12. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Iannettoni MD, Burdick MD,
Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC
chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic
pulmonary fibrosis. J Immunol 1997, 159(3):1437-1443.
13. Mukaida N, Shiroo M, Matsushima K: Genomic structure of the human
monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989,
143(4):1366-1371.
14. Arinir U, Klein W, Rohde G, Stemmler S, Epplen JT, Schultze-Werninghaus G:
Polymorphisms in the interleukin-8 gene in patients with chronic
obstructive pulmonary disease. Electrophoresis 2005, 26(15):2888-2891.
15. Hillian AD, Londono D, Dunn JM, Goddard KA, Pace RG, Knowles MR,
Drumm ML: Modulation of cystic fibrosis lung disease by variants in
interleukin-8. Genes Immun 2008, 9(6):501-508.
16. Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, Welsh K,
Bunn C, Knight C, Foley P, du Bois RM: Distribution of novel
polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in
systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum
2000, 43(7):1633-1640.
17. Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW,
Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY,
Park CS: Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis:
antiinflammatory and antifibrotic effect on experimental lung injury and
fibrosis. Am J Respir Crit Care Med 2010, 182(5):633-642.
18. Hedrick PW: Gametic disequilibrium measures: proceed with caution.
Genetics 1987, 117(2):331-341.
19. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype
reconstruction from population data. Am J Hum Genet 2001,
68(4):978-989.
20. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O’Brien TR,
Vlahov D, Buchbinder S, Giorgi J, Donfield S, Willoughby A, Smith MW:
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of
IL10. Proc Natl Acad Sci USA 2000, 97(26):14467-14472.
21. Menashe I, Rosenberg PS, Chen BE: PGA: power calculator for casecontrol
genetic association analyses. BMC Genet 2008, 9:36.
22. Hacking D, Knight JC, Rockett K, Brown H, Frampton J, Kwiatkowski DP,
Hull J, Udalova IA: Increased in vivo transcription of an IL-8 haplotype
associated with respiratory syncytial virus disease-susceptibility. Genes
Immun 2004, 5(4):274-282.
23. Heinzmann A, Ahlert I, Kurz T, Berner R, Deichmann KA: Association study
suggests opposite effects of polymorphisms within IL8 on bronchial
asthma and respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol
2004, 114(3):671-676.
24. Hull J, Thomson A, Kwiatkowski D: Association of respiratory syncytial
virus bronchiolitis with the interleukin 8 gene region in UK families.
Thorax 2000, 55(12):1023-1027.
25. Ross OA, O’Neill C, Rea IM, Lynch T, Gosal D, Wallace A, Curran MD,
Middleton D, Gibson JM: Functional promoter region polymorphism of
the proinflammatory chemokine IL-8 gene associates with Parkinson’s
disease in the Irish. Hum Immunol 2004, 65(4):340-346.
26. van der Kuyl AC, Polstra AM, Weverling GJ, Zorgdrager F, van den Burg R,
Cornelissen M: An IL-8 gene promoter polymorphism is associated with
the risk of the development of AIDS-related Kaposi’s sarcoma: a case-
control study. AIDS 2004, 18(8):1206-1208.
27. Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, Lin YP, Sheu ML, Li CP,
Chang FY, Chao Y, Yen SH, Lee SD: The -251T allele of the interleukin-8
promoter is associated with increased risk of gastric carcinoma featuring
diffusetype histopathology in Chinese population. Clin Cancer Res 2005,
11(18):6431-6441.
28. Dapas B, Tell G, Scaloni A, Pines A, Ferrara L, Quadrifoglio F, Scaggiante B:
Identification of different isoforms of eEF1A in the nuclear fraction of
human T-lymphoblastic cancer cell line specifically binding to aptameric
cytotoxic GT oligomers. Eur J Biochem 2003, 270(15):3251-3262.
doi:10.1186/1465-9921-12-73
Cite this article as: Ahn et al.: A promoter SNP rs4073T>A in the
common allele of the interleukin 8 gene is associated with the
development of idiopathic pulmonary fibrosis via the IL-8 protein
enhancing mode. Respiratory Research 2011 12:73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ahn et al. Respiratory Research 2011, 12:73
http://respiratory-research.com/content/12/1/73
Page 7 of 7